A Phase 2 Prospective, Randomized, Double-blind, Sham-controlled, Parallel-group, Multi-center Trial of AMI MultiStem Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2016
At a glance
- Drugs Allogeneic stem cell therapy Athersys (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms MI-NSTEMI
- Sponsors Athersys
- 16 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018.
- 16 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2017.
- 01 Jul 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.